Akeso Biopharma (stock code: 9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. Since the company's establishment, Akeso, Inc. has established an end-to-end comprehensive drug development platform (ACE Platform) and system, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC production process development, and GMP compliant scale production. The company has also successfully developed a bi-specific antibody drug development technology (Tetrabody technology). Akeso, Inc. currently has a pipeline of over 20 innovative drugs for the treatment of major diseases like tumors, autoimmune diseases, inflammation and metabolism diseases, 13 of which have entered clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The company's vision is to become a global leading biopharmaceutical company through research and development of high efficacy and breakthrough new drugs that are first-in-class and best-in-class therapies. Actively practicing corporate social responsibility, Akeso, Inc. is dedicated to developing next-generation affordable quality antibody drug for patients around the world, continues to provide better solutions for therapeutic treatments and health of all human beings.